Now I’m no surgeon, but I can guess that during surgery, there’s a lot of blood (actually, come to think of it, that’s part of the reason that I’m not a MD). Generally speaking, bleeding isn’t a good thing; Omrix’s biosurgical products and pipeline are designed to stop the bleeding (herein referred to by it’s […]
Filed under: Omrix Biopharmaceuticals (OMRI) | 7 Comments »
I’ve been hired as a freelance writer covering biotech companies for The Motley Fool, so posting frequency may drop off a little while I figure out my dual roles. I think this blog has potential and I don’t want to see it die (actually I’d like to see it grow), so if there’s anyone out […]
Filed under: This blog | 13 Comments »
The review of Omrix was a requested by a reader. If you would like me to review a relatively new biotech stock, you can e-mail me at hotmail.com with the username biologyfool before the at sign. If you include the info on this page in the e-mail, your chance of the stock getting […]
Filed under: Omrix Biopharmaceuticals (OMRI) | 14 Comments »
This is the sixth in a series of posts analyzing Rosetta Genomics stock.
The best thing that Rosetta Genomics has going for it is that it has a huge amount of intellectual property. They have patents on (or have licensed rights to) hundreds of miRNAs. Essentially, at this point, an investment in Rosetta Genomics […]
Filed under: Rosetta Genomics (ROSG) | 5 Comments »
This is the fifth in a series of posts analyzing Rosetta Genomics stock.
Most drugs that target proteins work by inhibiting the protein’s function. It’s simply a function of biology; it’s much easier to design a drug that will interfere with a protein’s function than it is to make it overactive. But sometimes (many […]
Filed under: Synta Pharmaceuticals (SNTA) | 9 Comments »
This is the fifth in a series of posts analyzing Rosetta Genomics stock.
Currently most tests for diseases look at protein (or sometimes mRNA) levels in the cells to determine if the cells are diseased. A good example of this is the prostrate specific antigen (PSA) test for prostrate cancer. The test looks at […]
Filed under: Rosetta Genomics (ROSG) | 5 Comments »
Does anyone have any idea why a company without any products to sell might be using Google adwords to advertise? I saw the image to the right on my blog the other day.
Here’s some potential ideas I came up with:
They’re trying to get even more research collaborations (but I would think anyone in the […]
Filed under: Rosetta Genomics (ROSG) | 6 Comments »
This is the third in a series of posts analyzing Rosetta Genomics stock.
When analyzing Synta, I decided to take a pass on buying their stock right now because I was worried that there wouldn’t be anyone to partner with them; Rosetta seems to have the opposite problem. Almost every product they’re developing has a […]
Filed under: Rosetta Genomics (ROSG) | 2 Comments »
This is the second in a series of posts analyzing Rosetta Genomics stock. If you haven’t already, you may want to read my primer on what a micro RNA is and how companies can capitalize on them.
There’s really two ways to find a miRNA. The first is to isolate RNA from the […]
Filed under: Rosetta Genomics (ROSG) | 1 Comment »
Before we get into investigating Rosetta Genomics in detail, I thought I would give a little background on micro RNAs since it’s the molecule that Rosetta has based its entire platform on.
Micro RNAs (miRNA) were discovered in worms about 14 years ago, but they have been found in a wide range of organisms (including humans) […]
Filed under: Back to the Basics | 4 Comments »